RxDoctor Payments Data

Daniel Pina

Physician Assistant · McAllen, TXNPI 1720479884

Payments from drug & device makers

$5,905in general payments, 2019–2025

Across 356 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$470
  • Lilly USA, LLC$467
  • GSK$459
  • Optinose US, Inc.$434
  • Boehringer Ingelheim$395
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$5,84299%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,905 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$123,638
JardianceEmpagliflozin85$102,402
LinzessLinaclotide57$72,974
FarxigaDapagliflozin Propanediol75$68,866
JanuviaSitagliptin Phosphate57$61,331
MounjaroTirzepatide38$59,892
MyrbetriqMirabegron49$46,529
TrulicityDulaglutide18$35,150
Tresiba Flextouch U-100Insulin Degludec39$33,931
XareltoRivaroxaban14$26,511
EliquisApixaban20$25,307
TrulancePlecanatide19$24,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$21,156
Breo ElliptaFluticasone/Vilanterol23$15,501
Tresiba Flextouch U-200Insulin Degludec11$14,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,070$123,63872 claims
Boehringer IngelheimJardiance$395$102,40285 claims
Lilly USA, LLCMounjaro, Trulicity$467$95,04256 claims
AbbVieLinzess$470$72,97457 claims
AstraZenecaFarxiga$381$68,86675 claims
MerckJanuvia$54$61,33157 claims
Astellas Pharma US IncMyrbetriq$264$46,52949 claims
GSKTrelegy Ellipta, Breo Ellipta$459$36,65744 claims
Johnson & JohnsonXarelto$151$26,51114 claims
PfizerEliquis$71$25,30720 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$388$24,55119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →